Literature DB >> 10584682

Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.

C Dentresangle1, L Veyre, D Le Bars, C Pierre, F Lavenne, P Pollak, J Guerin, J C Froment, E Brousolle.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10584682     DOI: 10.1002/1531-8257(199911)14:6<1025::aid-mds1020>3.0.co;2-p

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  6 in total

Review 1.  Functional neuroimaging in Parkinson's disease.

Authors:  Martin Niethammer; Andrew Feigin; David Eidelberg
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

2.  Positron emission tomography neuroimaging in Parkinson's disease.

Authors:  Clare Loane; Marios Politis
Journal:  Am J Transl Res       Date:  2011-07-10       Impact factor: 4.060

3.  Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.

Authors:  Kenji Ishibashi; Yuko Saito; Shigeo Murayama; Kazutomi Kanemaru; Keiichi Oda; Kiichi Ishiwata; Hidehiro Mizusawa; Kenji Ishii
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

4.  The direct basal ganglia pathway is hyperfunctional in focal dystonia.

Authors:  Kristina Simonyan; Hyun Cho; Azadeh Hamzehei Sichani; Estee Rubien-Thomas; Mark Hallett
Journal:  Brain       Date:  2017-12-01       Impact factor: 15.255

5.  Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients.

Authors:  Marios Politis; Heather Wilson; Kit Wu; David J Brooks; Paola Piccini
Journal:  Neuroimage Clin       Date:  2017-08-24       Impact factor: 4.881

Review 6.  Dopamine receptor mapping with PET imaging in Parkinson's disease.

Authors:  Flavia Niccolini; Paul Su; Marios Politis
Journal:  J Neurol       Date:  2014-03-15       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.